معرفی
Professor Jane Endicott is a distinguished structural biologist at Newcastle University's School of Natural and Environmental Sciences, where she serves as a Professor within the Institute for Cell and Molecular Biosciences. Her extensive research career spans over three decades, with continuous publication output from the 1980s through to 2025, demonstrating sustained scientific impact and leadership in her field. She maintains a highly active research program focused on the structural basis of cell cycle regulation and cancer drug discovery.
Professor Endicott's research interests center on understanding the molecular mechanisms of cyclin-dependent kinases (CDKs) and related cell cycle regulatory proteins through structural biology approaches. Her work has significantly advanced our understanding of protein-protein interactions in the cell cycle, particularly focusing on CDK-cyclin complexes, MDM2-p53 interactions, and ubiquitin-mediated protein degradation pathways. She employs cutting-edge techniques including X-ray crystallography, cryo-electron microscopy, and fragment-based screening to elucidate the structural basis of protein function and to guide rational drug design. Her research bridges fundamental structural biology with translational applications in cancer therapeutics, making significant contributions to the development of novel cancer treatments targeting cell cycle regulators.
Analysis of Professor Endicott's recent publications reveals a consistent focus on structural characterization of key cell cycle regulatory complexes and their application to cancer drug discovery. Her work demonstrates an evolving trajectory from fundamental structural studies of CDK-cyclin complexes to increasingly translational research involving fragment-based drug design, structure-based inhibitor development, and preclinical characterization of novel therapeutic compounds. The research shows particular strength in applying structural insights to understand kinase selectivity, protein-protein interactions, and mechanisms of drug action. Her most recent work continues to push methodological boundaries with advanced cryo-EM studies, innovative fragment screening approaches, and sophisticated structure-based drug design targeting multiple cancer-relevant pathways.
Throughout her career, Professor Endicott has maintained a highly productive collaborative network, most notably with Professor Martin Noble at Newcastle University, with whom she has co-authored numerous high-impact publications. Her research program has consistently attracted significant funding to support structural biology infrastructure, personnel, and drug discovery initiatives. She has supervised multiple PhD students and postdoctoral researchers who have gone on to successful careers in academia and industry.
Professor Endicott leads a dynamic structural biology research group that integrates crystallography, biophysical methods, and medicinal chemistry approaches to tackle fundamental questions in cell cycle regulation and cancer biology. Her laboratory maintains specialized facilities for protein expression, purification, and structural analysis, and collaborates extensively with medicinal chemists and cancer biologists to translate structural insights into therapeutic applications. The group's work continues to be at the forefront of structural approaches to understanding cell cycle control and developing novel cancer therapeutics.